Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Evaluation of Obesity Management Recorded in Electronic Clinical History: A Cohort Study. [PDF]
J Clin Med, 2020 Trujillo-Garrido N +2 more
europepmc +1 more source
Natural History Studies and the EUROSCA Clinical Research Network
, 2010 Thomas Klockgether
openalex +2 more sources
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Erratum: Neves KVRN, Machado LMG, Lisboa MN, Steinmann P, Ignotti E. Self-reported clinical history of misdiagnosed leprosy cases in the State of Mato Grosso, Brazil, 2016-2019. Cad Saúde Pública 2023; 39(5):e00279421. [PDF]
Cad Saude Publica, 2023 europepmc +1 more source
Some History of Clinical Sociology and Sociological Practice, Part I
, 1995 David J. Kallen
openalex +1 more source
Clinical histories before hospitalization in gastric cancer cases.
, 1986 Katsuhiro SANADA +8 more
openalex +2 more sources
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
ERRATUM: MMBGR Protocol - infants and preschoolers: instructive and orofacial myofunctional clinical history. [PDF]
Codas, 2023 europepmc +1 more source